Advertisement


Yukio Suzuki, MD, PhD, on Endometrial Cancer: Long-Term Survival Outcomes With Hormonal Therapy in Reproductive-Age Patients

2024 ASCO Annual Meeting

Advertisement

Yukio Suzuki, MD, PhD, of Columbia University College of Physicians and Surgeons, discusses data showing that reproductive-age patients with early-stage endometrial cancer who use fertility-preserving hormonal therapy seemed to have good overall survival after a 10-year follow-up (Abstract 5508).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
What we are going to look at is to determine the trends in and use of primary hormonal therapy use, and also long-term survival outcomes for hormonal therapy in premenopausal patient with early stage endometrial cancer. The design of this study is retrospective cohort study, and we use national cancer database which registered around 70% of newly diagnosed cases in the US. We have two major parts in this study and the fourth one is looking at the trends in and patterns of use of primary hormonal therapy in the premenopausal patient with early stage endometrial cancer. And the second one is survival outcome for the patient with early stage endometrial cancer. We included patients 18 to 49 years old and clinical stage 1 endometrial cancer and grade one [inaudible 00:01:01] 2 endometrial cancer. Main finding of our study is the utilization rate of primary hormonal therapy rose from 4% to 5% around 2004 to 2010, and it's going up to 12% to 14% in 2020. Younger age, non-white race patients who live in metropolitan area, patient who are treated at academic cancer center, patient who are treated at the facilities located at Northeast area in the US were associated with primary hormonal therapy use. In terms of tumor characteristics, grade 1 and stage 1A were associated with primary hormonal therapy use. For survival outcomes, the propensity score match cohort is well-balanced between the two primary treatment group. Overall, after 10 year follow up, the survival rate was decreased by 4.1% in hormonal therapy group compared with hysterectomy group. Hazard ratio was 1.84. In age subgroup, patient younger than 40 years old, the two primary treatment group of the survival rate was similar at any time point, five year and 10 year point. Surprisingly among age 40 to 49, the survival rate was inferior in hormonal therapy group then hysterectomy group at five year point and 10 year point. Hazard ratio was 4.94. To conclude, given the growing number of patient with early stage endometrial cancer who may desire fertility preservation, we need to consider potentially poorer prognosis when patients and provider select the primary hormonal therapy use. Shared decision making is further needed for this space and also prospective study with large sample sites should be needed for making this evidence more robust.

Related Videos

Breast Cancer

Milana Bergamino Sirvén, MD, PhD, on HER2-Positive Early-Stage Breast Cancer: Molecular Profiling, Prognosis, and Treatment Options

Milana Bergamino Sirvén, MD, PhD, of Spain’s Institute of Cancer Research, discusses her findings on molecular profiling of patients with estrogen receptor–positive, HER2-positive early-stage breast tumors after short-term preoperative endocrine therapy. This study suggests that such profiling may help clinicians identify those patients with a favorable prognosis for adjuvant endocrine therapy and those who may require additional treatment (Abstract 560).

Kidney Cancer

Brian I. Rini, MD, on Renal Cell Carcinoma: Exploratory Biomarker Results

Brian I. Rini, MD, of Vanderbilt Ingram Cancer Center, discusses phase III findings of the KEYNOTE-426 study of pembrolizumab plus axitinib vs sunitinib for patients with advanced renal cell carcinoma. He details the exploratory biomarker results, including RNA sequencing, whole-exome sequencing, and PD-L1 (Abstract 4505).

Gynecologic Cancers

Katherine C. Fuh, MD, PhD, on Ovarian Cancer: New Data on Batiraxcept and Paclitaxel

Katherine C. Fuh, MD, PhD, of the University of California, San Francisco, discusses phase III findings of the AXLerate-OC trial, showing that batiraxcept with paclitaxel compared to paclitaxel alone improved progression-free and overall survival in patients with platinum-resistant recurrent ovarian cancer whose tumors were AXL-high in an exploratory analysis (LBA5515).

Breast Cancer

Ciara C. O’Sullivan, MD, MBBCh, on HER2-Positive Breast Cancer: Expert Commentary on Treatments Under Study

Ciara C. O’Sullivan, MD, MBBCh, of Mayo Clinic, discusses three studies of treatment for patients with HER2-positive metastatic breast cancer and their clinical implications: the EMERALD trial of eribulin and taxane; the Patricia Cohort C trial of palbociclib plus trastuzumab and endocrine therapy; and DB07 on trastuzumab deruxtecan with or without palbociclib.

Colorectal Cancer

Jeanne Tie, MD, MBChB, on Colon Cancer: New Data on ctDNA Guiding Adjuvant Therapy

Jeanne Tie, MD, MBChB, of Peter MacCallum Cancer Centre, discusses data on survival and updated 5-year results from the DYNAMIC trial, which supports a role for circulating tumor DNA (ctDNA) analysis, including serial sampling, in the management of patients with stage II colon cancer (Abstract 108).

Advertisement

Advertisement




Advertisement